QIDP Designations
Executive Summary
Qualified Infectious Disease Product Designations granted by FDA. Updated upon new designations.
You may also be interested in...
Rx For Industry: Key Provisions Of The 21st Century Cures Act
Changes to the priority review voucher program, economic communications with payors, and approval of antimicrobial products all have the potential to impact the commercial prospects of drugmakers.
FDA Warning Letter Brings Another High-Flying Emergent CDMO Plant Down To Earth
Warning letter reveals agency found quality problems at Emergent BioSolutions’ Camden fill/finish plant during COVID-19 pandemic even as firm’s Bayview plant came under heightened scrutiny. Metal particulates appeared in vials as Camden plant and rest of Emergent’s CDMO network experienced sharp demand growth.
Amylyx ALS Drug: ICER Revised Evidence Report Casts Doubt On Firm’s New Data Analyses
ICER’s take on the Amylyx analyses raises questions about whether FDA will take a similar view and suggests payers may restrict coverage upon approval, at least initially, should it carry a very high price tag.